Coronary disease & ACSMeta-analysis

Individual patient data meta-analysis of paclitaxel-coated balloons vs. drug-eluting stents for small-vessel coronary artery disease: the ANDROMEDA study

Eur Heart JPublished

  • Individual patient data meta-analysis of randomised trials
  • collaborative
  • investigator-initiated

Authors' conclusion

In patients undergoing PCI for de novo SV-CAD, PCB angioplasty is associated with a reduction in MACE and a non-significant difference in TLF at 3 year follow-up compared with DES implantation.

Study context

Population
Patients undergoing percutaneous coronary intervention (PCI) for de novo small-vessel CAD
Participants
1,154 patients · 3 RCTs · 1,360 lesions
Comparison
Paclitaxel-coated balloon (PCB) angioplasty vs drug-eluting stent (DES) implantation
Outcome
MACE (primary) and target lesion failure (co-primary)
Follow-up
3 years

Pooled result

As reported in the abstract

Hazard ratio

0.67

95% CI 0.47–0.96

PCB vs DES
HR 0.67 (95% CI 0.47–0.96)

Further pooled results

OutcomeHR (95% CI)
TLF, PCB vs second-generation DES · 3 years · second-generation DES only; no significant difference1.03 (0.70–1.50)

Major adverse cardiac events (MACE), multivariable-adjusted · 3 years

Benefit persisted after multivariable adjustment
HR 0.75, 95% CI 0.58-0.96

MACE, two-stage analysis · 3 years

Did not reach statistical significance in the two-stage analysis
HR 0.67, 95% CI 0.43-1.04

MACE, landmark analysis

Risk of MACE between groups consistent over time

Target lesion failure (TLF), sensitivity analysis including reconstructed data from a fourth trial (1384 patients, 1590 lesions)

Consistent results in terms of TLF
HR 0.87, 95% CI 0.63-1.20

Original publication

Individual patient data meta-analysis of paclitaxel-coated balloons vs. drug-eluting stents for small-vessel coronary artery disease: the ANDROMEDA study. Eur Heart J. Published 21 February 2025. doi:10.1093/eurheartj/ehaf002

Summarised from the published abstract; every number is checked against it